Back to Journals » HIV/AIDS - Research and Palliative Care » Volume 13

Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia

Authors Muche Belete A, Seifu D, Menon M, Amogne W, Shewa A, Adela Tefera A

Received 7 December 2020

Accepted for publication 11 February 2021

Published 19 February 2021 Volume 2021:13 Pages 217—227

DOI https://doi.org/10.2147/HIV.S296170

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Bassel Sawaya


Abebe Muche Belete,1 Daniel Seifu,2 Menakath Menon,3 Wondwossen Amogne,4 Aster Shewa,5 Alemu Adela Tefera1

1Department of Biochemistry, Medical Faculty, Debre Berhan University, Debre Berhan, Ethiopia; 2Department of Biochemistry, Division of Biomedical Sciences, University of Global Health Equity, Kigali, Rwanda; 3Department of Biochemistry, Medical Faculty, Addis Ababa University, Addis Ababa, Ethiopia; 4Department of Internal Medicine, Medical Faculty, Addis Ababa University, Addis Ababa, Ethiopia; 5Department of Internal Medicine, Zewditu Memorial Hospital, Addis Ababa, Ethiopia

Correspondence: Abebe Muche Belete
Department of Biochemistry, Medical Faculty, Debre Berhan University, P.O. Box 445, Debre Berhan, Ethiopia
Email abebemuche3@gmail.com

Background: Dyslipidemia represents significant health care concerns in patients taking antiretroviral therapy due to their association with cardiovascular disease risk. There is limited data regarding the effects of boosted atazanavir (ATV/r) treatment in the lipid profiles of Ethiopian HIV patients. Thus, this study compares the mean values of lipid profile differences of HIV patients on ATV/r-based regimen compared to efavirenz (EFV)-based regimen, while the background is Tenofovir Disoproxil Fumarate/lamivudine.
Materials and Methods: A comparative hospital-based cross-sectional study was conducted among adult HIV-infected patients at Zewditu Memorial Hospital, Addis Ababa, Ethiopia, from July–September 2017. An equal number of EFV and ATV/r-treated patients (n=90 each) receiving for 1-year and over were included in the study. Serum total cholesterol (TC), triglyceride (TG), gigh-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) were measured. Data comparison used chi-square test, Student’s t-test and Mann–Whitney U-test. Multivariate logistic regression analysis and p-value< 0.05 were used to identify associated factors of serum lipid profiles.
Results: In the present study, the ATV/r-treated group results were significantly higher in the median values of TG [207 (56– 1094) vs 145 (42– 768) mg/dL; p=0.001] and the mean value of TG/HDL-c (6.6 vs 4.4; p=0.001) as compared to the EFV-treated group. The EFV-treated group showed significantly higher in the mean value of HDL-c (44.7 vs 38.7 mg/dL; p=0.001) as compared to the ATV/r-treated group. Body mass index was associate with LDL and HDL. CD4 was associated with TC. Current antiretroviral therapy was associated with TG. Duration of HIV since first diagnosis and duration of ART were associated with HDL.
Conclusion: ATV/r is associated with elevated in TG and TG/HDL-C, but low HDL as compared to EFV. Differences in LDL or HDL that were found were of unclear clinical significance. The long-term significance is unknown.

Keywords: dyslipidemia, antiretroviral therapy, efavirenz, ritonavir-boosted atazanavir

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]